Go offline with the Player FM app!
First AI Antibody In Humans with Aulos' Aron Knickerbocker
Manage episode 428977106 series 2739469
We love to hear from our listeners. Send us a message.
Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Bristol-Myers Squibb and Genentech to his leadership of Aulos Bioscience, a company that boasts the first AI-generated antibody in human clinical trials. We explore Aulos' innovative IL-2 antibody and the role AI played in its highly-targeted and toxicity-reducing design, and we do it in pragmatic fashion — Aron's not about the AI hype, he's about the AI data — and in its Phase 1/2 clinical trial, the data is looking pretty good.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapters
1. Bioprocess Online's BioExpo Live (00:00:00)
2. Career Decisions in Biopharma Transition (00:08:26)
3. Building a Biopharma Career Journey (00:17:10)
4. Rising Biopharma Ventures and Courageous Decision-Making (00:25:54)
5. Innovations in IL-2 Antibody Design (00:42:30)
6. AI Influence on IL-2 Antibody Design (00:48:19)
7. Update on Phase 2 Clinical Trials (01:01:39)
215 episodes
Manage episode 428977106 series 2739469
We love to hear from our listeners. Send us a message.
Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Bristol-Myers Squibb and Genentech to his leadership of Aulos Bioscience, a company that boasts the first AI-generated antibody in human clinical trials. We explore Aulos' innovative IL-2 antibody and the role AI played in its highly-targeted and toxicity-reducing design, and we do it in pragmatic fashion — Aron's not about the AI hype, he's about the AI data — and in its Phase 1/2 clinical trial, the data is looking pretty good.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Chapters
1. Bioprocess Online's BioExpo Live (00:00:00)
2. Career Decisions in Biopharma Transition (00:08:26)
3. Building a Biopharma Career Journey (00:17:10)
4. Rising Biopharma Ventures and Courageous Decision-Making (00:25:54)
5. Innovations in IL-2 Antibody Design (00:42:30)
6. AI Influence on IL-2 Antibody Design (00:48:19)
7. Update on Phase 2 Clinical Trials (01:01:39)
215 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.